Octreolin is an investigational oral form of the peptide octreotide, a somatostatin analog that’s available only by injection commercially. Genentech will market the product in the United States after US FDA authorization. Chiasma will continue development through completion of the pivotal phase 3 medical trial for acromegaly. The arrangement includes an upfront payment to Chiasma of $65 million, future considerations of up to $530 million in development and commercial milestones, in addition to tiered, double-digit royalties on Octreolin net sales.Meanwhile, two feasible conflicts of curiosity with users of the FDA advisory panels possess emerged in the last couple of days. The Wall Road Journal discovered that David Capuzzi, among the three panelists who voted to keep Avandia on market without fresh warnings, was paid $14,750 by GSK, at least $6,750 which came after 2008. Capuzzi says he was paid to discuss lipid-lowering drug called Lovaza, but a GSK spokesman informed Pharmalot that at least one chat ahead of 2008 was for Avandia. On the contrary end of the vote, Abraham Thomas, among twelve users of the panel who suggested withdrawing Avandia from the marketplace, was paid $2,000-$3,000 by Takeda Pharmaceuticals between 2007 and 2008.